» Articles » PMID: 23555935

HIV-1 P24(gag) Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice

Abstract

Viral diversity is considered a major impediment to the development of an effective HIV-1 vaccine. Despite this diversity, certain protein segments are nearly invariant across the known HIV-1 Group M sequences. We developed immunogens based on the highly conserved elements from the p24(gag) region according to two principles: the immunogen must (i) include strictly conserved elements of the virus that cannot mutate readily, and (ii) exclude both HIV regions capable of mutating without limiting virus viability, and also immunodominant epitopes located in variable regions. We engineered two HIV-1 p24(gag) DNA immunogens that express 7 highly Conserved Elements (CE) of 12-24 amino acids in length and differ by only 1 amino acid in each CE ('toggle site'), together covering >99% of the HIV-1 Group M sequences. Altering intracellular trafficking of the immunogens changed protein localization, stability, and also the nature of elicited immune responses. Immunization of C57BL/6 mice with p55(gag) DNA induced poor, CD4(+) mediated cellular responses, to only 2 of the 7 CE; in contrast, vaccination with p24CE DNA induced cross-clade reactive, robust T cell responses to 4 of the 7 CE. The responses were multifunctional and composed of both CD4(+) and CD8(+) T cells with mature cytotoxic phenotype. These findings provide a method to increase immune response to universally conserved Gag epitopes, using the p24CE immunogen. p24CE DNA vaccination induced humoral immune responses similar in magnitude to those induced by p55(gag), which recognize the virus encoded p24(gag) protein. The inclusion of DNA immunogens composed of conserved elements is a promising vaccine strategy to induce broader immunity by CD4(+) and CD8(+) T cells to additional regions of Gag compared to vaccination with p55(gag) DNA, achieving maximal cross-clade reactive cellular and humoral responses.

Citing Articles

Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119.

Kalams S, Felber B, Mullins J, Scott H, Allen M, De Rosa S JCI Insight. 2024; 9(18).

PMID: 39088271 PMC: 11466283. DOI: 10.1172/jci.insight.180819.


Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses.

Olvera A, Romero-Martin L, Oriol-Tordera B, Rosas-Umbert M, Escriba T, Mothe B Vaccines (Basel). 2024; 12(3).

PMID: 38543913 PMC: 10975332. DOI: 10.3390/vaccines12030279.


No Difference in the Prevalence of HIV-1 Cytotoxic T-Lymphocyte-Associated Escape Mutations in Viral Sequences from Early and Late Parts of the HIV-1 Subtype C Pandemic in Botswana.

Mokaleng B, Choga W, Bareng O, Maruapula D, Ditshwanelo D, Kelentse N Vaccines (Basel). 2023; 11(5).

PMID: 37243104 PMC: 10221913. DOI: 10.3390/vaccines11051000.


Efficient expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates.

Dross S, Venkataraman R, Patel S, Huang M, Bollard C, Rosati M Front Immunol. 2023; 14:1188018.

PMID: 37207227 PMC: 10189133. DOI: 10.3389/fimmu.2023.1188018.


Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV conserved elements in macaques.

Valentin A, Bergamaschi C, Rosati M, Angel M, Burns R, Agarwal M Front Immunol. 2022; 13:945706.

PMID: 35935984 PMC: 9355630. DOI: 10.3389/fimmu.2022.945706.


References
1.
Kent S, Fernandez C, Dale C, Davenport M . Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends Microbiol. 2005; 13(6):243-6. DOI: 10.1016/j.tim.2005.03.011. View

2.
Mothe B, Ibarrondo J, Llano A, Brander C . Virological, immune and host genetics markers in the control of HIV infection. Dis Markers. 2009; 27(3):105-20. PMC: 3835054. DOI: 10.3233/DMA-2009-0655. View

3.
Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, von Gegerfelt A . Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine. 2011; 29(39):6742-54. PMC: 3115438. DOI: 10.1016/j.vaccine.2010.12.056. View

4.
Frahm N, Nickle D, Linde C, Cohen D, Zuniga R, Lucchetti A . Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. AIDS. 2008; 22(4):447-56. DOI: 10.1097/QAD.0b013e3282f42412. View

5.
Ngumbela K, Day C, Mncube Z, Nair K, Ramduth D, Thobakgale C . Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res Hum Retroviruses. 2008; 24(1):72-82. DOI: 10.1089/aid.2007.0124. View